Staccato® Granisetron Single Dose PK

NCT04200092 | Completed Phase 1 DMC FDA Drug FDA Device

• 1 other identifier: AMDC-010-101
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

This study was conducted in 2 parts in separate treatment groups of healthy volunteers. Part A of the study was double-blind, randomized, and placebo-controlled; Part B is open label. The primary objectives for each part were as follows: Part A:

1. 1.To examine the tolerability and safety of single ascending doses up to 3 mg of AZ-010 (Staccato Granisetron) in healthy volunteers
2. 2.To characterize the pharmacokinetics (PK) of single ascending doses up to 3 mg of AZ-010 in healthy volunteers

Conditions

Healthy

Outcome Measures

Primary Outcomes (4)

• Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).

  Number of Subjects with Adverse Events as a Measure of Safety and Tolerability

  3 days

• Measurement of Granisetron Exposure in Plasma

  AUC (area under the curve)

  3 days

• Measurement of Granisetron Maximum Exposure in Plasma

  Cmax

  3 days

• Measurement of Granisetron Time to Maximum Exposure in Plasma

  Tmax

  3 days

Study Arms (6)

Part A: Cohort 1

EXPERIMENTAL

A single oral dose of 0.5 mg AZ-010 (Staccato Granisetron) administered to 8 subjects, with at least 2 males and 2 females. Each subject received a single dose of 0.5 mg AZ-010, or matching Staccato® placebo; 6 subjects received AZ-010 and 2 subjects received Staccato® placebo. Upon completion of the cohort, a review of the in-clinic safety and tolerability data was performed by the PI, Medical Monitor, and an independent data safety monitoring board (DSMB) to determine if there were adequate safety and tolerability data to support escalation to the next dose. Safety was evaluated by the PI, Medical Monitor, and DSMB upon completion of Part A and prior to start of Part B. Each subject participated for up to 4 weeks, depending upon the timing of screening. Subjects were confined to the clinic for 4 days (3 nights). A follow-up phone call was conducted, approximately 7 days after the subject left the CRU.

Combination Product: 0.5mg AZ-010; placebo

Part A: Cohort 2

EXPERIMENTAL

A single oral dose of 1 mg AZ-010 (Staccato Granisetron) administered to 8 subjects, with at least 2 males and 2 females. Each subject received a single dose of 1 mg AZ-010, or matching Staccato® placebo; 6 subjects received AZ-010 and 2 subjects received Staccato® placebo. Upon completion of the cohort, a review of the in-clinic safety and tolerability data was performed by the PI, Medical Monitor, and an independent data safety monitoring board (DSMB) to determine if there were adequate safety and tolerability data to support escalation to the next dose. The single daily dose did not exceed 3 mg. Safety was evaluated by the PI, Medical Monitor, and DSMB upon completion of Part A and prior to start of Part B. Each subject participated for up to 4 weeks, depending upon the timing of screening. Subjects were confined to the clinic for 4 days (3 nights). A follow-up phone call was conducted, approximately 7 days after the subject left the CRU.

Combination Product: 1mg AZ-010

Part A: Cohort 3

EXPERIMENTAL

A single oral dose of 3 mg AZ-010 (Staccato Granisetron) administered to 8 subjects, with at least 2 males and 2 females. Each subject received a single dose of 3 mg AZ-010, or matching Staccato® placebo; 6 subjects received AZ-010 and 2 subjects received Staccato® placebo. Upon completion of the cohort, a review of the in-clinic safety and tolerability data was performed by the PI, Medical Monitor, and an independent data safety monitoring board (DSMB) to determine if there were adequate safety and tolerability data to support escalation to the next dose. The single daily dose did not exceed 3 mg. Safety was evaluated by the PI, Medical Monitor, and DSMB upon completion of Part A and prior to start of Part B. Each subject participated for up to 4 weeks, depending upon the timing of screening. Subjects were confined to the clinic for 4 days (3 nights). A follow-up phone call was conducted, approximately 7 days after the subject left the CRU.

Combination Product: 3mg AZ-010

Part B: Sequence 1

ACTIVE COMPARATOR

A single inhalation dose of 1 mg AZ-010, followed by IV injection granisetron 1mg, 2-period, a 2-treatment open-label crossover design. Participants were randomized in a 1:1 ratio to 1 of 2 sequences. Period 1 began with the inhalation dose of AZ-010 1mg and after a three-day washout participants were crossed over to the other sequence for Period 2 with the treatment of IV injection granisetron 1 mg dose. There was a total of 12 subjects (6 subjects in each sequence, with at least 2 males and 2 females in each sequence). Sequence 1 participants crossed over to Sequence 2 after washout.

Combination Product: AZ-010 1mg; Drug: IV Granisetron 1mg

Part B: Sequence 2

ACTIVE COMPARATOR

Treatment of 1 mg (IV) granisetron followed by a single inhalation dose of AZ-010 1mg, a 2-period, 2-treatment open-label crossover design. Part B Sequence 2 participants began with Period 1 treatment of IV injection granisetron 1 mg dose and after a three-day washout participants were crossed over to the other sequence for Period 2 with the inhalation dose of AZ-010 1mg. There was a total of12 subjects (6 subjects in each sequence, with at least 2 males and 2 females in each sequence). Sequence 2 participants crossed over to Sequence 1 after washout.

Combination Product: AZ-010 1mg; Drug: IV Granisetron 1mg

Pooled Placebo, Cohort 1, 2, 3 Part A

PLACEBO COMPARATOR

Participants in Part A, Cohorts 1, 2, and 3, double-blind, randomized, and placebo-controlled study who received placebo.

Other: Placebo

Interventions

3mg AZ-010 COMBINATION_PRODUCT

Subject will receive a single inhaled dose (3.0 mg) of AZ-010 or matching Staccato Placebo

Also known as: Staccato Granisetron 3mg

Part A: Cohort 3

AZ-010 1mg COMBINATION_PRODUCT

2-period, 2-treatment open-label crossover design

Also known as: Staccato Granisetron 1mg

Part B: Sequence 1; Part B: Sequence 2

IV Granisetron 1mg DRUG

2-period, 2-treatment open-label crossover design

Also known as: Granisetron HCl, supplied as a 1 mg/mL solution (Lot No. 061488A)

Part B: Sequence 1; Part B: Sequence 2

Placebo OTHER

Participants in Part A, Cohorts 1, 2, and 3, double-blind, randomized, and placebo-controlled study who received placebo.

Pooled Placebo, Cohort 1, 2, 3 Part A

0.5mg AZ-010; placebo COMBINATION_PRODUCT

Subject will receive a single inhaled dose (0.5mg) of AZ-010 or matching Staccato Placebo

Also known as: Staccato Granisetron 0.5 mg

Part A: Cohort 1

1mg AZ-010 COMBINATION_PRODUCT

Subject will receive a single inhaled dose (1.0 mg) of AZ-010 or matching Staccato Placebo

Also known as: Staccato Granisetron 1mg

Part A: Cohort 2

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy adult males and females between 18 and 60 years of age, inclusive at the time of signing the informed consent document.
• Female subjects fulfilled the following criteria:
• Surgically sterile (including bilateral tubal ligation) for at least 3 months prior to screening
• Postmenopausal, defined as 1 of the following:
• Last menstrual sequence greater than 12 months prior to screening
• Last menstrual sequence greater than 6 months prior to screening and a serum follicle-stimulating hormone (FSH) concentration \> 40 mIU/mL
• Subjects of childbearing potential (i.e., did not meet the criteria for surgical sterility or post- menopausal status outlined above):
• Had a negative serum pregnancy test at screening and Day -1, as verified by the study doctor prior to starting study therapy
• Either committed to true abstinence from heterosexual contact or agreed to use, and was able to comply with, effective contraception without interruption with one of the following methods during the study participation up until 90 days after administration of study drug: Oral contraceptive medications, Intrauterine devices, Hormonal implants, Injectable contraceptive medications, Double barrier methods.
• Male subjects practiced true abstinence from heterosexual contact or, during sexual contact with a pregnant female or a female of childbearing potential, agreed to use a condom.
• Healthy, as determined by the responsible physician, based on a medical evaluation including history, physical examination, vital signs, ECGs, and laboratory tests assessed at the screening visit and prior to the first dose of study drug.
• Body weight ≥ 50 kg and BMI within the range of 18 to 32 kg/m2, inclusive, at screening.
• Negative urine tests for selected drugs of abuse and alcohol breath test at screening and Day 1.
• Dietary habits that fell within the range of normal, as determined by the PI.
• Was willing and able to be confined at the clinical research center for the study period, and adhered to overall study visit schedule, procedures and other protocol requirements.

You may not qualify if:

• Subject candidates were not enrolled in the study if they met any of the following criteria:
• Any significant medical condition, psychiatric illness or history of depression that could have, in the PI's opinion, compromised the subject's safety or interfered with the completion of this study.
• Any condition, including the presence of laboratory abnormalities or abnormal pulmonary function test, which according to the PI, placed the subject at unacceptable risk if he/she were to participate in the study.
• Any condition that according to the PI confounded the ability to interpret data from the study such as a virus, seasonal allergy, concurrent skin rash, etc. at screening or prior to drug treatment phase that may have been difficult to discern from further health status changes from an investigational product.
• History of clinically significant central nervous system (e.g., seizures), cardiac, pulmonary (e.g., asthma, chronic obstructive pulmonary disease), metabolic, renal, hepatic, or gastrointestinal (GI) conditions including gastric bypass or other weight loss surgical procedure; or history of such conditions that, in the opinion of the PI, may have placed the subject at an unacceptable risk as a participant in this trial, may have interfered with the interpretation of safety and/or tolerability data obtained in the trial, or may have interfered with the absorption, distribution, metabolism, or excretion of the study drugs.
• Used drugs known to prolong the corrected QT interval (QTc).
• PR interval \> 220 msec or QRS duration \> 120 msec or Fridericia's corrected QT interval (QTcF) \> 450 msec for men and \> 470 msec for women obtained at the screening visit or prior to the first dose of study drug.
• Aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl transferase (GGT), serum creatinine, or total bilirubin \> 1.5 upper limit of normal (ULN) at screening or prior to the first dose of study drug.
• Positive blood screen for HIV antibody, hepatitis B virus surface antigen (HBsAg), or hepatitis C virus (HCV) antibody at screening.
• History of drug or alcohol abuse within 6 months of screening.
• History of any tobacco product use within 3 months prior to the study.
• Participation in a clinical trial and receipt of an investigational medication or a new chemical entity within 90 days, 5 half-lives, if known, or twice the duration of the biological effect of any medication (whichever is longer) prior to the first dose of current study drug.
• Use of non-prescription medications, including herbal and dietary supplements within 5 days or 5 half-lives (whichever was longer) prior to the first dose of study drug.
• Use of any 5-HT3 receptor antagonists or any other serotonergic drugs, including selective serotonergic reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs) within 5 days or 5 half-lives (whichever is longer) prior to screening.
• Consumption of any caffeine and/or xanthine products (i.e., coffee, tea, chocolate and caffeine containing sodas, colas, etc.) within 24 hours prior to entry to the clinical unit on Day -1.

Sponsors & Collaborators

• Celerion: collaborator
• Nova Pneuma Inc.: lead

Study Sites (1)

Celerion

Tempe, Arizona, 85283, United States

Location

MeSH Terms

Interventions

Granisetron; Equipment and Supplies; Solutions

Intervention Hierarchy (Ancestors)

Azabicyclo Compounds; Aza Compounds; Organic Chemicals; Indazoles; Pyrazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Bridged Bicyclo Compounds, Heterocyclic; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Pharmaceutical Preparations

Study Officials

• Phillip Mathew, MD

  Celerion

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 20, 2019
• First Posted: December 16, 2019
• Study Start: November 4, 2019
• Primary Completion: January 10, 2020
• Study Completion: January 31, 2020
• Last Updated: April 13, 2026

Record last verified: 2026-04

Locations

US (1)